-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Intellectual Property
IPCC Features Update on Patent Reform Implementation
The BIO Intellectual Property Counsels Committee Fall Conference featured an update on the implementation of the Leahy-Smith America Invents Act by Janet Gongola, Associate Solicitor of the U.S. Patent and Trademark Office (PTO). Some provisions of the Leahy-Smith America Invents Act took effect immediately when it was signed into law in September. Ms. Gongola reported that of the 20 provisions that must be implemented by the PTO, eight have been implemented and another ten are Read More >
The Critical Importance of International Patent Protection for Small Businesses
As part of the implementation of the Leahy-Smith America Invents Act, the U.S. Patent and Trademark Office (PTO) recently held two public hearing on international patent protection. Stanley C. Erck, President and CEO of Novavax, Inc., testified on behalf of BIO in support of an initiative to reduce filing and prosecution costs for international patent protection of biotech inventions. In his testimony, Mr. Erck explained the important role patents play in the biotechnology industry. The Read More >
KORUS and BIO’s New Senior Vice President for International Affairs
Earlier this week, Joseph Damond joined BIO as Senior Vice President of International Affairs. He brings extensive experience in international affairs, trade and economics, most recently serving as Vice President of International Government Relations at Pfizer, Inc. He previously served as Deputy Vice President for International Affairs at PhRMA and as the Deputy Assistant for the Asia-Pacific region in the Office of the U.S. Trade Representative. Joe will spearhead BIO’s international trade policy and help Read More >
Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2)
The Trans Pacific Partnership (TPP) negotiation does not yet include a section on data protection (typically included in the Pharmaceutical Chapter of Free Trade Agreements). Organizations against the inclusion of data protection in the TPP cite as evidence an Oxfam International study titled “All Costs, No Benefits: How TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines.” The Oxfam paper concludes that “medicine prices have increased drastically, and TRIPS-plus rules were partly Read More >
Non-Communicable Diseases and IP?
On September 19 and 20, the United Nations meets to potentially adopt a declaration on non-communicable diseases similar to the 2001 Declaration of Commitment on HIV/AIDS. The diseases of particular focus include cardiovascular disease, diabetes, cancer, and respiratory disease. Similar to previous UN initiatives around HIV/AIDS, the meeting will focus on developmental, social and economic impacts and other challenges, particularly for developing countries. UN background documents mention IP and it is possible that UN negotiations may Read More >
